Global Neurogenic Orthostatic Hypotension Market Size, Share, and COVID-19 Impact Analysis, By Type (Norepinephrine Reuptake Inhibitors and Adrenergic Medications), By Application (Clinic and Hospital), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2025 - 2035

Global Neurogenic Orthostatic Hypotension Market Insights Forecasts to 2035

• The Global Neurogenic Orthostatic Hypotension Market Size Was Estimated at USD 403.0 Million in 2024
• The Market Size is Expected to Grow at a CAGR of around 7.08% from 2025 to 2035
• The Worldwide Neurogenic Orthostatic Hypotension Market Size is Expected to Reach USD 855.0 Million by 2035
• Asia Pacific is expected to grow the fastest during the forecast period.

According to a research report published by Spherical Insights and Consulting, the global neurogenic orthostatic hypotension market size was worth around USD 403.0 million in 2024 and is predicted to grow to around USD 855.0 million by 2035 with a compound annual growth rate (CAGR) of 7.08% from 2025 and 2035. The market for neurogenic orthostatic hypotension has a number of opportunities to grow due to update in treatment approach via combining drug treatment of OH with non-pharmacological approaches like intermittent water bolus treatment, use of physical counter maneuvers, and compression of the venous capacitance bed.

Market Overview

The Global Neurogenic Orthostatic Hypotension Market Size is the industry for treatments, diagnostics, and management solutions for this condition, which is a form of low blood pressure upon standing caused by autonomic nervous system dysfunction. Neurogenic orthostatic hypotension is the condition characterized by a fall in systolic blood pressure (SBP) of >=20mmHg or diastolic blood pressure (DBP) of >=10 mmHg, within 3 minutes of standing. The condition is commonly found in elderly patients, which is estimated to be 233 per 100,000 patients, affected with neurodegenerative disorders and peripheral neuropathies, caused by inadequate vasomotor sympathetic release or norepinephrine due to autonomic dysfunction. For diagnosis, bedside orthostatic test, head-up tilt table test, and 25-h ambulatory blood pressure monitoring are some of the tests, while for treatment, midodrine, droxidopa, and fludrocortisone are commonly administered medications. There is an increasing research on optimizing drug effects for neurogenic orthostatic hypotension, which is anticipated to drive a huge surge in the market.

Report Coverage

This research report categorizes the neurogenic orthostatic hypotension market based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the neurogenic orthostatic hypotension market. Recent market developments and competitive strategies such as expansion, type launch, development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the neurogenic orthostatic hypotension market. 

Driving Factors

The increasing prevalence of neurogenic orthostatic hypotension, with an increased prevalence of Parkinson’s disease, is significantly contributing to driving the neurogenic orthostatic hypotension market. It was estimated that the point prevalence of orthostatic hypotension in Parkinson’s Diseases was found to be 30.1%. The growing initiative programs for building awareness about nervous system disorders are contributing to propel the market. For instance, in October 2025, Theravance Biopharma, Inc. announced the launch of “Power in the Periphery”, a new disease education campaign for healthcare professionals to raise awareness and deepen scientific understanding of the pathophysiology underlying neurogenic orthostatic hypotension (nOH) associated with Multiple System Atrophy (MSA). Further, advancement in treatment approaches, including the use of pyridostigmine and non-pharmacological approaches combined with drug treatment, is propelling the market growth.

Restraining Factors

The neurogenic orthostatic hypotension market is restricted by the potential side effects and safety concerns related to treatment. Further, the associated challenges like inadequate training and strict regulations associated with clinical trials & approvals are hampering the market growth.

Market Segmentation

The neurogenic orthostatic hypotension market share is classified into type and application.   

• The norepinephrine reuptake inhibitors segment dominated the market with the largest share of about 60.0% in 2024 and is projected to grow at a substantial CAGR during the forecast period.

Based on the treatment, the neurogenic orthostatic hypotension market is divided into norepinephrine reuptake inhibitors and adrenergic medications. Among these, the norepinephrine reuptake inhibitors segment dominated the market with the largest share of about 60.0% in 2024 and is projected to grow at a substantial CAGR during the forecast period. Norepinephrine reuptake inhibitors (NRIs) are primarily used in patients with normal or high norepinephrine levels. These drugs have proven to reduce symptoms of neurogenic orthostatic hypotension on a single administration of selective NRI atomoxetine. Further, an ongoing investigation of NRI drugs for treating symptoms related to neurogenic orthostatic hypotension is anticipated to drive the market.  

• The hospital segment accounted for the largest market share of about 50% in 2024 and is anticipated to grow at a significant CAGR during the forecast period.

Based on the application, the neurogenic orthostatic hypotension market is divided into clinic and hospital. Among these, the hospital segment accounted for the largest market share of about 50% in 2024 and is anticipated to grow at a significant CAGR during the forecast period. Neurogenic orthostatic hypotension is a common cause of hospitalizations, accounting for 80,000 hospitalizations every year in the U.S. In a hospitalized condition, initial treatment modalities include removal of offending medications, using non-pharmacologic measures, followed by the addition of pharmacologic medications. The presence of advanced medical equipment and specialized staff in the hospital is responsible for driving the market.

Regional Segment Analysis of the Neurogenic Orthostatic Hypotension Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

North America is anticipated to hold the largest share of the neurogenic orthostatic hypotension market over the predicted timeframe.

North America is anticipated to hold the largest share of about 38-47% in the neurogenic orthostatic hypotension market over the predicted timeframe. The market ecosystem in North America is strong, with an increasing investigation by the biopharmaceutical companies in drugs for neurogenic orthostatic hypotension. The market demand for neurogenic orthostatic hypotension has been driven by the region's increasing investment in developing innovative treatment, with an increasing technological advancements and medical research. Further, the ongoing study on developing therapeutic strategies and diagnostic tests contributing to propel market growth. For instance, in may 2022, frontiers published a review article on ‘Dysautonomia in COVID-19 Patients: A Narrative Review on Clinical Course, Diagnostic and Therapeutic Strategies’. The United States is dominating the North America neurogenic orthostatic hypotension market with a major share in 2024, owing to the increased pharmaceutical spending, advanced healthcare accessibility, and upsurging awareness regarding the condition.

Asia Pacific is expected to grow at a rapid CAGR of nearly 7.8-8.0% in the neurogenic orthostatic hypotension market during the forecast period. The Asia Pacific area has a thriving market for neurogenic orthostatic hypotension due to the increasing prevalence of comorbidities like diabetes and Parkinson’s, along with the rapid urbanization and lifestyle changes. China and Japan are leading the Asia Pacific region in the neurogenic orthostatic hypotension market, accounting for 38% and 19.8% share, respectively. This is attributed to the increasing innovation in targeting prevalent chronic conditions as well as Japan’s increasing ageing demographic, which are responsible factors for driving the development of novel dosing technologies.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the neurogenic orthostatic hypotension market, along with a comparative evaluation primarily based on their type of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes type development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Lundbeck
• Chelsea Therapeutics
• Northera Pharmaceuticals
• Theravance Biopharma
• Sumitomo Pharmaceuticals
• Shire PLC
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Development

• In October 2025, Theravance Biopharma, Inc. announced the launch of “Power in the Periphery”, a new disease education campaign for healthcare professionals (HCPs) to raise awareness and deepen scientific understanding of the pathophysiology underlying neurogenic orthostatic hypotension (nOH) associated with Multiple System Atrophy (MSA).

• In August 2025, Theravance Biopharma, Inc. announced the completion of enrollment in the open-label portion of its pivotal Phase 3 CYPRESS study in enrollment in the open-label portion of its pivotal Phase 3 CYPRESS study in patients with symptomatic neurogenic orthostatic hypotension (nOH) due to multiple system atrophy (MSA), a rare and progressive neurodegenerative disorder.

• In November 2023, Theravance Biopharma, Inc. announced that a new, anchor-based analysis of ampreloxetine data in neurogenic orthostatic hypotension (nOH) would be presented at the 34th International Symposium on the Autonomic Nervous System, a meeting of the American Autonomic Society (AAS), taking place November 15-18, 2023, in Rio Grande, Puerto Rico.

• In September 2021, Global pharma major Lupin Limited announced the launch of Droxidopa Capsules, 100mg, 200mg, and 300mg, having received approval from the United States Food and Drug Administration (US FDA). Droxidopa Capsules (RLD: Northera) had estimated annual sales of USD 294 million in the U.S.

Market Segment

This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the neurogenic orthostatic hypotension market based on the below-mentioned segments: 

Global Neurogenic Orthostatic Hypotension Market, By Type

• Norepinephrine Reuptake Inhibitors
• Adrenergic Medications

Global Neurogenic Orthostatic Hypotension Market, By Application

• Clinic
• Hospital

Global Neurogenic Orthostatic Hypotension Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa